222 related articles for article (PubMed ID: 11447380)
1. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model.
Paltiel AD; Fuhlbrigge AL; Kitch BT; Liljas B; Weiss ST; Neumann PJ; Kuntz KM
J Allergy Clin Immunol; 2001 Jul; 108(1):39-46. PubMed ID: 11447380
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity.
Sin DD; Golmohammadi K; Jacobs P
Am J Med; 2004 Mar; 116(5):325-31. PubMed ID: 14984818
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.
Wilson EC; Price D; Musgrave SD; Sims EJ; Shepstone L; Murdoch J; Mugford HM; Blyth A; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Hillyer EV; Harvey I
Pharmacoeconomics; 2010; 28(7):597-608. PubMed ID: 20446755
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density.
Fuhlbrigge AL; Bae SJ; Weiss ST; Kuntz KM; Paltiel AD
J Allergy Clin Immunol; 2006 Feb; 117(2):359-66. PubMed ID: 16461137
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
[TBL] [Abstract][Full Text] [Related]
7. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma.
Buendía JA; Patiño DG
BMC Pulm Med; 2021 Dec; 21(1):398. PubMed ID: 34865635
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.
Wilson EC; Sims EJ; Musgrave SD; Shepstone L; Blyth A; Murdoch J; Mugford HM; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Harvey I; Hillyer EV; Price D
Pharmacoeconomics; 2010; 28(7):585-95. PubMed ID: 20550224
[TBL] [Abstract][Full Text] [Related]
10. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M; Briggs AH; Grossman RF; Rance L
Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
Han S; Kim S; Kim H; Suh HS
Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
[No Abstract] [Full Text] [Related]
12. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524
[TBL] [Abstract][Full Text] [Related]
13. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma.
Rodríguez-Martínez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2013 May; 50(4):410-8. PubMed ID: 23356720
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
16. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma.
Rutten-van Mölken MP; Van Doorslaer EK; Jansen MC; Van Essen-Zandvliet EE; Rutten FF
Pharmacoeconomics; 1993 Oct; 4(4):257-70. PubMed ID: 10146915
[TBL] [Abstract][Full Text] [Related]
18. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.
Wu AC; Gay C; Rett MD; Stout N; Weiss ST; Fuhlbrigge AL
Pharmacogenomics; 2015; 16(6):591-600. PubMed ID: 25880024
[TBL] [Abstract][Full Text] [Related]
20. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective.
Campbell JD; Spackman DE; Sullivan SD
Allergy; 2010 Sep; 65(9):1141-8. PubMed ID: 20148804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
